<DOC>
	<DOCNO>NCT00375453</DOCNO>
	<brief_summary>This study evaluate safety tolerability SH U04722 patient solid tumor cancer . In addition , study identify recommend dose administration schedule SH U04722 phase II development Japanese cancer patient , evaluate pharmacokinetic profile SH U04722 gather preliminary data effectiveness SH U04722 patient solid tumor .</brief_summary>
	<brief_title>Dose Escalation Study SH U04722 Solid Tumors</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<criteria>Refractory conventional antineoplastic treatment standard therapy option availableECOG Performance Status score &lt; 2Agreement take vitamin E product Juvela ( except overthecounter [ OTC ] diet supplement ) . Patients treat unapproved drugs/investigational drug , chemotherapy , biological response modifier , immunotherapy endocrinotherapy within 4 week prior entry study nitrosoureas within 6 week initial dose SH U04722 Patients concurrent therapy warfarin coumarin derivatives.Patients radiation therapy within 2 week prior entry study . Patients history serious hypersensitivity taxanes.Patients current peripheral neuropathy ( ? Common Terminology Criteria Adverse Events [ CTCAE ] Grade 2 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>